507132539 02/16/2022

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7179380

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	

Name	Execution Date
BART RUDOLF ROMANIE KESTELEYN	01/30/2020
JAN MARTIN BERKE	01/28/2020
ERWIN COESEMANS	01/27/2020
SANDRINE CELINE GROSSE	01/29/2020
EDGAR JACOBY	01/28/2020
TIM HUGO MARIA JONCKERS	01/29/2020
WIM GASTON VERSCHUEREN	04/08/2020
STEFAAN JULIEN LAST	03/20/2020

RECEIVING PARTY DATA

Name:	JANSSEN PHARMACEUTICA NV	
Street Address:	SS: TURNHOUTSEWEG 30	
City:	ity: BEERSE	
State/Country:	/Country: BELGIUM	
Postal Code:	B-2340	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16867249

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email:	liz.seggern@icemiller.com
Correspondent Name:	ICE MILLER LLP
Address Line 1:	1735 MARKET STREET
Address Line 2:	SUITE 3900
Address Line 4:	PHILADELPHIA, PENNSYLVANIA 19103

ATTORNEY DOCKET NUMBER: 065814.11521/117US1	
NAME OF SUBMITTER:	LIZ SEGGERN
SIGNATURE:	/Liz Seggern/

DATE SIGNED:	02/16/2022	
Total Attachments: 32	·	
source=Assignment inventors to JP NV	V#page1.tif	
source=Assignment inventors to JP NV#page2.tif		
source=Assignment inventors to JP NV#page3.tif		
source=Assignment inventors to JP NV#page4.tif		
source=Assignment inventors to JP NV#page5.tif		
source=Assignment inventors to JP NV#page6.tif		
source=Assignment inventors to JP NV#page7.tif		
source=Assignment inventors to JP NV#page8.tif		
source=Assignment inventors to JP NV#page9.tif		
source=Assignment inventors to JP NV#page10.tif		
source=Assignment inventors to JP N	V#page11.tif	
source=Assignment inventors to JP N	V#page12.tif	
source=Assignment inventors to JP N	V#page13.tif	
source=Assignment inventors to JP NV#page14.tif		
source=Assignment inventors to JP N	V#page15.tif	
source=Assignment inventors to JP N	V#page16.tif	
source=Assignment inventors to JP N	V#page17.tif	
source=Assignment inventors to JP NV#page18.tif		
source=Assignment inventors to JP N	V#page19.tif	
source=Assignment inventors to JP N	V#page20.tif	
source=Assignment inventors to JP N	V#page21.tif	
source=Assignment inventors to JP N	V#page22.tif	
source=Assignment inventors to JP N	V#page23.tif	
source=Assignment inventors to JP N	V#page24.tif	
source=Assignment inventors to JP N	V#page25.tif	
source=Assignment inventors to JP N	V#page26.tif	
source=Assignment inventors to JP N	V#page27.tif	
source=Assignment inventors to JP NV#page28.tif		
source=Assignment inventors to JP NV#page29.tif		
source=Assignment inventors to JP NV#page30.tif		
source=Assignment inventors to JP NV	V#page31.tif	
source=Assignment inventors to JP NV	V#page32.tif	

Between

KESTELEYN, Bart Rudolf Romanie (hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium. (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 6th day of May 2019, European Patent Application no. EP19172736.1 was filed at the European Patent Office;

and

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and Improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor agrees that this general assignment is effective from the 6th day of May 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

KESTELEYN, Bart Rudolf Romanie

DAELEMANS, Frank Janssen Pharmaceutica NV Authorized Signatory

Signature Date:

30 January 2020

Between

BERKE, Jan Martin (hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium, (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HEV INFECTION OF HEV-INDUCED DISEASES"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 6th day of May 2019, European Patent Application no. EP19172736.1 was filed at the European Patent Office;

and

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor agrees that this general assignment is effective from the 6th day of May 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

BERKE, Jan Martin

DAELEMANS, Frank Janssen Phaimaceutica NV Authorized Signatory

Signature Date: 28 Junuary 2020

Between

COESEMANS, Erwin

(hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium. (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 6th day of May 2019, European Patent Application no. EP19172736.1 was filed at the European Patent Office;

and

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desircus of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assigner for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor agrees that this general assignment is effective from the 6th day of May 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

and the second second

COESEMANS, Erwin

DAELEMANS, Frank Janssen Pharmaceutica NV Authorized Signatory

Signature Date: 27 January 2020

Between

GROSSE, Sandrine Céline

(hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium. (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OF HBV-INDUCED DISEASES"

(hereinalter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 6th day of May 2019, European Patent Application no. EP19172736.1 was filed at the European Patent Office;

and

WHEREAS, the conditions under which said invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entities Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assigner for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor agrees that this general assignment is effective from the 6th day of May 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

GROSSE, Sandrine Cèline

DAELEMANS, Frank Janssen Pharmaceutica NV Authorized Signatory

Signature Date:

2.9 January 2020 Seatt

Between

JACOBY, Edgar

(hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium. (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HEV INFECTION OR HEV-INDUCED DISEASES"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 6th day of May 2019, European Patent Application no. EP19172736.1 was filed at the European Patent Office;

and

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewais, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor agrees that this general assignment is effective from the 6th day of May 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

JACØBY, Edgar

DAELEMANS, Frank Janssen Pharmaceutica NV Authorized Signatory

Signature Date:

28. Jonuary 2020

Between

JONCKERS, Tim Hugo Maria

(hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium, (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HEV INFECTION OR HEV-INDUCED DISEASES"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 6th day of May 2019, European Patent Application no. EP19172736.1 was filed at the European Patent Office; and

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assigner for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assigner covenants that the Assigner has the full right and obligation to convey the interest assigned by this Assignment, and the Assigner has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor agrees that this general assignment is effective from the 6th day of May 2019,

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

JONCKERS, Tim Hugo Maria

DAELEMANS, Frank Janssen Pharmaceutica NV Authorized Signatory

Signature Date:

203 January 2020

TIP1018

General Assignment

Between

VERSCHUEREN, Wim Gaston (hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium. (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES"

(hereinafter referred to as "invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 6th day of May 2019, European Patent Application no. EP19172736.18 was filed at the European Patent Office;

and

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereoi, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW. THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor If this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor agrees that this general assignment is effective from the 6th day of May 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

VERSCHUEREN, Wim Gaston

DAELEMANS, Frank Janssen Pharmaceutica NV Authorized Signatory

Signature Date:

8 April 2020

TIP1018

General Assignment

Between

LAST, Stefaan Jullen (hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium. (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-Inventor of the Invention,

for which on the 6th day of May 2019, European Patent Application no. EP19172736.1 was filed at the European Patent Office; and

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor agrees that this general assignment is effective from the 6th day of May 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

LAST, Stefaan Julien

DAELEMANS, Frank Janssen Pharmaceutica NV Authorized Signatory

Signature Date: 20/03/2020

Between

LAST, Stefaan Julien

(hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium. (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES"

(hereinafter referred to as "invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 6th day of May 2019, European Patent Application no. EP19172736.1 was filed at the European Patent Office; and

WHEREAS, the conditions under which said invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assigner for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor agrees that this general assignment is effective from the 6th day of May 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

all

LAST, Stefaan Julien

DAELEMANS/Frank Janssen Pharmaceutica NV Authorized Signatory

Signature Date:

Signature Date:

1 April 2020

Between

KESTELEYN, Bart Rudolf Romanie

(hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium. (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 6th day of May 2019, European Patent Application no. EP19172736.1 was filed at the European Patent Office;

and

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor agrees that this general assignment is effective from the 6th day of May 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

DAELEMANS, Frank Janssen Pharmaceutica NV Authorized Signatory

Signature Date:

KESTELEYN, Bart Rudolf Romanie

Signature Date:

a April 2020

Between

JONCKERS, Tim Hugo Maria (hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium. (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 6th day of May 2019, European Patent Application no. EP19172736.1 was filed at the European Patent Office;

and

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor agrees that this general assignment is effective from the 6th day of May 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

DAELEMANS, Frank Janssen Pharmaceutica NV Authorized Signatory

Signature Date:

JONCKERS, Tim Hugo Maria

Signature Date:

1 April

Between

JACOBY, Edgar

(hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium. (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 6th day of May 2019, European Patent Application no. EP19172736.1 was filed at the European Patent Office;

and

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and Improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor agrees that this general assignment is effective from the 6th day of May 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

JACOBY, Edgar

Signature Date:

DAELEMANS, Frank Janssen Pharmaceutica NV Authorized Signatory

Signature Date:

1 April 2020

Between

GROSSE, Sandríne Céline

(hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium. (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 6th day of May 2019, European Patent Application no. EP19172736.1 was filed at the European Patent Office;

and

WHEREAS, the conditions under which said invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor agrees that this general assignment is effective from the 6th day of May 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

GROSSE, Sandrine Céline

DAELEMANS, Frank Janssen Pharmaceutica NV Authorized Signatory

Signature Date:

Signature Date:

Between

BERKE, Jan Martin

(hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium. (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 6th day of May 2019, European Patent Application no. EP19172736.1 was filed at the European Patent Office;

and

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor agrees that this general assignment is effective from the 6th day of May 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

BERKE, Jan Martin

DAELEMANS, Frank Janssen Pharmaceutica NV Authorized Signatory

Signature Date: fril co 20

Between

COESEMANS, Erwin

(hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium. (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 6th day of May 2019, European Patent Application no. EP19172736.1 was filed at the European Patent Office;

and

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor agrees that this general assignment is effective from the 5th day of May 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

DAELEMANS, Frank Janssen Pharmaceutica NV Authorized Signatory

Signature Date:

COESEMANS, Erwin

Signature Date: fuil 2020 1

Between

VERSCHUEREN, Wim Gaston (hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium. (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 6th day of May 2019, European Patent Application no. EP19172736.18 was filed at the European Patent Office;

and

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor agrees that this general assignment is effective from the 6th day of May 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

VERSCHUEREN, Wim Gaston

DAELEMANS, Frank Janssen Pharmaceutica NV Authorized Signatory

Signature Date:

Signature Date:

24 April Lolo

PATENT REEL: 059112 FRAME: 0960

RECORDED: 02/16/2022